MedTrace Logo

AGN-151597 (Formerly RST-001) Phase I/II Trial for Advanced Retinitis Pigmentosa

NCT02556736 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2026-01-12

Study results available
· View outcomes & findings →

Summary

All participants in phase 1 and phase 2a had hand motion visual acuity or worse.

If efficacy was demonstrated from phase 1, better vision subjects could be enrolled; however, efficacy was not demonstrated.

Conditions

  • Advanced Retinitis Pigmentosa

Interventions

DRUG

AGN-151597

AGN-151597 is a gene therapeutic delivered by intravitreal injection

Sponsors & Collaborators

Principal Investigators

  • ABBVIE INC. · AbbVie

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-14
Primary Completion
2020-06-01
Completion
2024-10-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02556736 on ClinicalTrials.gov